- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02053961
Deep TMS of the Left Auditory Cortex Using the HMCIPCC Coil, in the Treatment of Patients With Tinnitus.
The Efficacy of dTMS Among Patient Who Suffer From Tinnitus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stages of the study:
A. Patient recruitment stage: hearing tests battery including: otoscopy, tympanometry, pure-tone audiometry - 0 to 20 dB HL; 21 to 60 dB HL and more than 60 dB HL, tinnitus matching, TQ and VAS.
B. Patients will be assign to one of two study groups, Deep TMS over the left auditory cortex and Sham. .
C. TMS Acute treatment phase:
TMS treatment will be administer for two weeks: 5 days a week for half an hour. Before each TMS treatment session, patients will undergo training exercises designed to stimulate the neural network associated with attention processes Monitoring for evaluation of treatment efficacy and side effects will be perform on a daily basis. . The overall time of each session is estimate to be 1 hour.
D. TMS Maintenance phase:
Four additional TMS treatment sessions will be administered once weekly for another 4 weeks.
Long-term durability of treatment effect will be assessed up to 90 days after the last TMS session.
E. TMS treatment program:
- The subject will be required to use earplugs to minimize risk of hearing impairment.
- Motor threshold stimulation intensity will be determined prior to each TMS session. .
- Subjects will receive either active TMS or sham treatment, depending on the experimental group to which they were assign. During the first 2 weeks, five treatment sessions will be administer each week. During the following 4 weeks, one treatment will be administer weekly. Overall, each subject will receive 16 TMS session in 6 treatment weeks.
F. Safety:
Throughout the trial subjects will be constantly monitored by a physician. Any adverse effect or subjective discomfort experienced will be documented and addressed.
Magnetic stimulation treatment will be administered by an operator trained and certified by Brainsway.
Subjects who wish to withdraw from the study will be free to do so at any point.
Drugs belonging to benzodiazepine class will be permitted if necessary at daily doses up to the equivalent of 2 mg Lorazepam (Lorivan).
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Holon, Israel
- Wolfson Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged 20-70.
- Self-report of tinnitus in one or both ears, persisting for over a year, with no other hearing impairment.
- Mild/moderate/severe tinnitus. Severity of tinnitus will be diagnosed using the TQ (Goebel & Hiller) / the THI (Newman & Jacobson).
- Unresponsive to standard tinnitus medication.
- Normal results on pure tone audiometry testing (threshold ≤ 25 dB hearing level in all frequencies from 250 to 8000 Hz).
- Normal middle ear status was demonstrated by tympanometry, stapedius reflex tests, and otoscopy.
- Normal results on neurological and physiological examinations.
- Gave their oral and written consent to participate in the trial.
Exclusion Criteria:
- A DSM-IV Axis-I psychiatric disorder.
Use of medication that may be a risk factor for seizures, such as:
antipsychotic medication; high dosage of antidepressant medication; drugs belonging to benzodiazepine class will be permitted if necessary at daily doses up to the equivalent of 2 mg Lorazepam (Lorivan)' any other drug that is considered a risk factor for seizures by the Principal Investigator.
- History of intolerance to TMS.
- Diagnosis of a severe personality disorder according to the DSM-IV.
- Current suicidal ideation.
- Uncontrolled hypertension.
- History of epilepsy, seizure, or heat convulsion.
- History of epilepsy or seizure in first degree relatives.
- History of head injury or stroke.
- History of any metallic particles in the head (except dental fillings).
- History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemakers, cochlear implants, use of neurostimulators, or any medical pumps.
- History of drug or alcohol abuse.
- Inability to communicate adequately with examiner.
- Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
- Inability to sign a consent form.
- Pregnancy or inadequate birth control.
- Severe hearing impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1Hz dTMS Real
This group will receive dTMS real treatment of 1Hz
|
1Hz dTMS real treatment
1Hz dTMS SHAM treatment
|
Sham Comparator: 1HZ dTMS SHAM
This group will receive 1HZ dTMS SHAM treatment
|
1Hz dTMS real treatment
1Hz dTMS SHAM treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
TQ - Tinnitus questionnaire
Time Frame: 90 days after the last treatment session
|
90 days after the last treatment session
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
VAS (100 - worst possible tinnitus related discomfort; 0 - wellness)
Time Frame: baseline, week 1: day 1-5, and week 2: day 1-5
|
baseline, week 1: day 1-5, and week 2: day 1-5
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yair Lampel, Prof., Neurology Department, Wolfson Hospital, Israel
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- dTMS-Tinnitus- wolfson
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinnitus
-
State University of New York at BuffaloUniversity at BuffaloCompletedTinnitus, Subjective | Tinnitus | Noise Induced Tinnitus | Tinnitus, Objective | Tinnitus Aggravated | Tinnitus, Pulsatile | Tinnitus, Spontaneous Oto-Acoustic Emission | Tinnitus, Clicking | Tinnitus, Tensor Tympani InducedUnited States
-
Mohab MohammedNot yet recruitingPulsatile Tinnitus (Diagnosis)
-
Philipps University Marburg Medical CenterLinkoeping University; Eriksholm Research Centre; University Hospital of Gießen...CompletedTinnitus | Subjective Tinnitus | Chronic TinnitusGermany
-
University of GuadalajaraHospital Civil de Guadalajara; Institute of Experimental and Clinical TherapeuticsRecruitingOxidative Stress | Tinnitus, Subjective | Tinnitus, Bilateral | Antioxidant Therapy | Psychiatric Drugs | Inflammatory Cytokines | SSRIMexico
-
University Hospital, BordeauxNot yet recruiting
-
Cairo UniversityRecruiting
-
University of ZurichRecruitingTinnitus, Subjective | TinnitusSwitzerland
-
Eye & ENT Hospital of Fudan UniversityNot yet recruiting
-
University of Illinois at Urbana-ChampaignGN Hearing A/SActive, not recruitingTinnitus, SubjectiveUnited States
-
University of ZurichCompletedTinnitus, SubjectiveGermany, Switzerland
Clinical Trials on Deep Transcranial Magnetic Stimulation
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingMajor Depressive DisorderCanada
-
Shanghai Mental Health CenterShanghai University of Traditional Chinese Medicine; Shanghai Tongji Hospital... and other collaboratorsNot yet recruitingFeeding and Eating DisordersChina
-
Douglas Mental Health University InstituteBrainswayCompletedMajor Depressive DisorderCanada
-
Shanghai Mental Health CenterRecruitingTreatment Resistant Schizophrenia Based on the DTMSChina
-
Shenzhen Kangning HospitalThe National Natural Science Foundation of China (NSFC)Not yet recruitingAnxiety State | Anxiety Disorder
-
Maimónides Biomedical Research Institute of CórdobaIsaac Tunez-Fiñana; Eduardo Agüera-MoralesUnknownMultiple Sclerosis
-
University of Sao Paulo General HospitalUnknownSmoking Cessation | Transcranial Magnetic StimulationBrazil
-
University of Roma La SapienzaCompletedGlioblastoma Multiforme of Brain
-
Hadassah Medical OrganizationCompleted
-
Shalvata Mental Health CenterBrainsway-moach Ltd.Unknown